GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business update

30 Apr 2007 07:49

ViaLogy PLC30 April 2007 Date: 30 April 2007On behalf of: ViaLogy plc ("ViaLogy" or "the Company") For immediate release ViaLogy PLC Business Update Vialogy SPMTM selected by US Department of Defence for joint experiments todevelop Joint Forces Protection and Base Security Systems London, April 30, 2007 -- ViaLogy PLC (LSE: VIY), announces that its Americansubsidiary, ViaLogy LLC, has been chosen by the US Department of Defence (DoD)to participate in joint experiments to support next-generation Joint ForceProtection Advanced Security (JFPASS) Joint Capabilities TechnologyDemonstration (JCTD). ViaLogy was selected to provide a Command and Controlplatform for the experiments. Recent DoD studies have found that current technologies, as employed, do notprovide a comprehensive, integrated and sustainable Joint Force Protectioncapability. The goal of JFPASS is to address these shortcomings with a potential$60 million combined services project to begin in 2008. The JFPASS JCTD is a joint services (Army, Navy, Air Force and Marines)initiative for integrating tactical systems, sensors and security personnel toprotect forces and over 600 facilities in the US and overseas. NATO and othercoalition partners have similar needs for base and force protection globally. ViaLogy will be providing its SPMTM (Sensor Policy Manager) product for theinternet protocol-enabled sensors and systems to accurately and immediatelyinterpret and disseminate information to pre-selected destinations. The lack ofsuch an effective interoperability between systems has previously been asignificant problem for both the military and public sectors. At a recent integration assessment supporting JFPASS JCTD in the Space and NavalWarfare Systems Centre (SPAWAR), San Diego, CA, ViaLogy successfullydemonstrated interoperability between two disparate operators, NorthropGrumman's Tactical Asset Security System (TASS) and the Joint BattlespaceCommand and Control Station (JBC2S) for unmanned systems. ViaLogy has alsointegrated a Lightweight Chemical Detector (LCD) from Smiths Detection tovalidate the IP-based plug-and-play capabilities of SPMTM. The LCD is part ofthe soldiers' hand-held equipment and is used for checking cargo, personnel orbuildings for chemical warfare agents. ViaLogy's SPMTM product provides a sensor-based policy engine for the rapiddetection, analysis and transmission of information. It exploits internetprotocol and patented signal processing to deliver interoperability to sensor,video and network sub-systems. Of major importance to potential users of SPMTM are its reliability,adaptability and affordability. "The product is designed for scaleableimplementation involving hundreds and even thousands of sensors," said Dr.Sandeep Gulati, ViaLogy's Chief Technology Officer. "JFPASS requirements presentan ideal opportunity for SPMTM. The technology thrives on the unexpected and, inthe event of a major incident, plays a vital role in detection and effectivedamage control." Previously, as NASA's Jet Propulsion Laboratory PrincipalScientist for sensor fusion, Dr. Gulati was extensively involved with sensorintensive command and control systems. ViaLogy CEO, Mr. Shah Talukder stated: "Higher demand for commercialoff-the-shelf products will shift procurement from project-centric toproduct-centric acquisition of technology. This will drive down project costsand timelines as it does in private sector procurement." Mr. Talukder who, prior to joining ViaLogy, developed the vision, strategy androad map for Cisco's Interoperability and Collaboration System (IPICS), added: "By delivering comprehensive sensor, video and tactical interoperability in anetwork-centric platform we believe SPM product will be able to meet JFPASS JCTDrequirements and play an integral part in the joint forces security project." For further information please contact: ViaLogy Shah Talukder, CEO - US +1 626-296-6337Terry Bond, Chairman - UK & Europe +44 (0)20 2869 7014 Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0)20 7822 0200 Seymour Pierce Limited (NOMAD)Mark Percy +44 (0)20 7107 8000 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications. ViaLogy is currently deploying and designingcomputational systems, powered by its patented technologies, for applications inlife sciences, public safety and security, surveillance, defense andgeoseismology. Vialogy focuses on market driven problems where automation,timeliness, quality and reliability of information processing are essential.ViaLogy's core competency incorporates rapidly and accurately detecting weaksignals buried in high noise background and clutter. This technology can beemployed to solve problems involving sensor integration and information overloadchallenges involving video, telephony and control sensors, as well as forenhancement of numerous signal processing applications. For more information,visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
25th Jan 20237:00 amRNSDirectorate Change
18th Jan 202312:07 pmRNSDirector/PDMR Shareholding
17th Jan 202312:06 pmRNSHolding(s) in Company
13th Jan 20234:27 pmRNSDirector/PDMR Shareholding
13th Jan 20231:03 pmRNSHolding(s) in Company
12th Jan 20233:48 pmRNSHolding(s) in Company
12th Jan 20232:43 pmRNSHolding(s) in Company
11th Jan 202312:23 pmRNSHolding(s) in Company
11th Jan 202311:29 amRNSHolding(s) in Company
11th Jan 202311:26 amRNSDirector/PDMR Shareholding
9th Jan 20235:25 pmRNSResult of General Meeting and Retail Offer
6th Jan 20234:35 pmRNSClose of Retail Offer
6th Jan 20233:34 pmRNSHolding(s) in Company
29th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 20221:09 pmRNSDirector/PDMR Shareholding
23rd Dec 202211:29 amRNSHolding(s) in Company
23rd Dec 20227:00 amRNSPosting of Circular and Notice of General Meeting
22nd Dec 202211:00 amRNSRetail Offer
22nd Dec 20227:00 amRNSResult of Placing and Subscriptions
21st Dec 20222:29 pmRNSProposed Capital Raising
21st Dec 20222:25 pmRNSHalf-year Report
25th Nov 202211:00 amRNSPrice Monitoring Extension
3rd Nov 20227:00 amRNSFirst half trading update
27th Sep 20223:08 pmRNSResult of AGM
27th Sep 20227:00 amRNSAGM Statement
25th Aug 20227:00 amRNSNotice of AGM & Change of Registered Address
16th Aug 20227:00 amRNSOpen Day and advance notice of AGM
27th Jul 20227:00 amRNSAudited Final Results
27th Jul 20227:00 amRNSDr John Brown CBE confirmed as Chairman
11th Jul 20227:00 amRNSNotice of Final Results
24th May 20227:00 amRNSAccelerator Phase Launch for Microdeletions Plugin
12th May 202211:06 amRNSSecond Price Monitoring Extn
12th May 202211:00 amRNSPrice Monitoring Extension
12th May 20227:00 amRNSCEO share purchase
26th Apr 20227:01 amRNSDirectorate Change
26th Apr 20227:00 amRNSFull year trading update
25th Apr 20227:00 amRNSStrategic partnership extended with Ambry Genetics
12th Apr 20227:00 amRNSIssue of share options and total voting rights
6th Apr 20227:00 amRNSCapital Markets Day
21st Mar 20224:23 pmRNSDirector/PDMR Shareholding
17th Feb 20227:00 amRNSSuccessful CTDA desktop review
25th Jan 20227:00 amRNSDirectorate Change
24th Jan 20227:00 amRNSDirector Dealing
21st Jan 20222:48 pmRNSIssue of Equity & Total Voting Rights
19th Jan 20227:00 amRNSOpening of new Yourgene Health Canada facilities
19th Jan 20227:00 amRNSAgreement of new debt facility
18th Jan 20227:00 amRNSUS partnership with EKF for NIPT and genomic tests
17th Jan 20227:00 amRNSCurrent year trading update
23rd Dec 20217:00 amRNSDHSC contract award for COVID Winter surge testing
14th Dec 202111:00 amRNSUKHSA contract award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.